Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb

Journal for ImmunoTherapy of Cancer

Volumn 1, Issue , 2013, Pages

  Morales Kastresana, Aizea ^a   Catalán, Elena ^b   Hervás Stubbs, Sandra ^a   Palazón, Asis ^a   Azpilikueta, Arantza ^a   Bolaños, Elixabet ^a   Anel, Alberto ^b   Pardo, Julián ^b   Melero, Ignacio ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 MONOCLONAL ANTIBODY; FAS LIGAND; GAMMA INTERFERON; GRANZYME; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MONOCLONAL ANTIBODY; PERFORIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; IMMUNIZATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THYMOMA; TUMOR GROWTH; TUMOR REJECTION;

EID: 84991032493     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/2051-1426-1-3     Document Type: Article

References (19)

1. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I: Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010, 37:508-516.
2. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L: Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997, 3:682-685.
3. Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K, Chapoval AI, Strome SE, Pease LR, Chen L: Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 2002, 109:651-659.
4. Murillo O, Arina A, Hervas-Stubbs S, Gupta A, McCluskey B, Dubrot J, Palazon A, Azpilikueta A, Ochoa MC, Alfaro C, et al: Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res 2008, 14:6895-6906.
5. Murillo O, Dubrot J, Palazon A, Arina A, Azpilikueta A, Alfaro C, Solano S, Ochoa MC, Berasain C, Gabari I, et al: In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol 2009, 39:2424-2436.
6. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L: NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998, 190:167-172.
7. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Muller A, Pachynski R, Czerwinski D, Coutre S, et al: CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011, 117:2423-2432.
8. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW, et al: Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012, 122:1066-1075.
9. Palazon A, Martinez-Forero I, Teijeira A, Morales-Kastresana A, Alfaro C, Sanmamed MF, Perez-Gracia JL, Penuelas I, Hervas-Stubbs S, Rouzaut A, et al: The HIF-1alpha hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov 2012, 2:608-623.
10. Wilcox RA, Flies DB, Wang H, Tamada K, Johnson AJ, Pease LR, Rodriguez M, Guo Y, Chen L: Impaired infiltration of tumor-specific cytolytic T cells in the absence of interferon-gamma despite their normal maturation in lymphoid organs during CD137 monoclonal antibody therapy. Cancer Res 2002, 62:4413-4418.
11. Lopez JA, Brennan AJ, Whisstock JC, Voskoboinik I, Trapani JA: Protecting a serial killer: pathways for perforin trafficking and self-defence ensure sequential target cell death. Trends Immunol 2012, 33:406-412.
12. Pardo J, Aguilo JI, Anel A, Martin P, Joeckel L, Borner C, Wallich R, Mullbacher A, Froelich CJ, Simon MM: The biology of cytotoxic cell granule exocytosis pathway: granzymes have evolved to induce cell death and inflammation. Microbes Infect 2009, 11:452-459.
13. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ: Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011, 29:235-271.
14. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P: Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994, 265:528-530.
15. Brossart P, Goldrath AW, Butz EA, Martin S, Bevan MJ: Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 1997, 158:3270-3276.
16. Simon MM, Waring P, Lobigs M, Nil A, Tran T, Hla RT, Chin S, Mullbacher A: Cytotoxic T cells specifically induce Fas on target cells, thereby facilitating exocytosis-independent induction of apoptosis. J Immunol 2000, 165:3663-3672.
17. Pardo J, Balkow S, Anel A, Simon MM: The differential contribution of granzyme A and granzyme B in cytotoxic T lymphocyte-mediated apoptosis is determined by the quality of target cells. Eur J Immunol 2002, 32:1980-1985.
18. Pardo J, Perez-Galan P, Gamen S, Marzo I, Monleon I, Kaspar AA, Susin SA, Kroemer G, Krensky AM, Naval J, Anel A: A role of the mitochondrial apoptosis-inducing factor in granulysin-induced apoptosis. J Immunol 2001, 167:1222-1229.
19. Martinez-Lostao L, Garcia-Alvarez F, Basanez G, Alegre-Aguaron E, Desportes P, Larrad L, Naval J, Martinez-Lorenzo MJ, Anel A: Liposome-bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis. Arthritis Rheum 2010, 62:2272-2282.